Pfizer cans PF-08046045, but keeps PF-08046044 for now.
ApexOnco Front Page
Recent articles
The Fortitude-102 trial, testing a bemarituzumab/Opdivo/chemo triplet, has failed.
After Dren secured buy-in from Novartis, LTZ becomes a clinical player.
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
Interius, one of the most advanced players, will cost $350m.
Posters and mini-orals include another VEGF bispecific.
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Summit and Nuvalent have scored prized plenary spots.
